B Gallwitz

Summary

Affiliation: University Eye Hospital
Country: Germany

Publications

  1. doi 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
    Baptist Gallwitz
    Department of Medicine IV, Universitatsklinikum Tubingen, Tubingen, Germany
    Lancet 380:475-83. 2012
  2. doi Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
    Baptist Gallwitz
    Department of Medicine IV, Eberhard Karls University Tubingen, Tubingen, Germany
    Lancet 379:2270-8. 2012
  3. doi Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time
    B Gallwitz
    Department of Medicine IV, University Hospital of Tubingen, Tubingen, Germany
    Int J Clin Pract 64:267-76. 2010
  4. doi The risk allele load accelerates the age-dependent decline in beta cell function
    A Haupt
    Medical Clinic, Department of Internal Medicine IV Diabetology, Endocrinology, Nephrology, Angiology, and Clinical Chemistry, Eberhard Karls University, Otfried Muller Strasse 10, 72076, Tubingen, Germany
    Diabetologia 52:457-62. 2009
  5. doi A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion
    S A Schafer
    Department of Internal Medicine, Division of Endocrinology, University Hospital of Tubingen, Tubingen, Germany
    Diabetologia 52:1075-82. 2009
  6. doi Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas
    B Gallwitz
    Department of Internal Medicine IV, University of Tubingen, Tubingen, Germany
    Diabetes Obes Metab 12:1-11. 2010
  7. doi Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors
    K Müssig
    Division of Endocrinology, Department of Internal Medicine, University Hospital of Tubingen, Tubingen, Germany
    Horm Metab Res 42:599-606. 2010
  8. ncbi Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor
    M Haap
    Department of Endocrinology, Metabolism, Nephrology, Clinical Chemistry and Vascular Medicine, Eberhard Karls University of Tubingen, Tubingen, Germany
    J Endocrinol Invest 30:688-92. 2007
  9. doi Lymph node gastrinoma in multiple endocrine neoplasia type 1 - a diagnostic challenge
    K Müssig
    Division of Endocrinology, Diabetology, Nephrology, Angiology, and Clinical Chemistry, Department of Internal Medicine, University Hospital of Tubingen, Tubingen, Germany
    Exp Clin Endocrinol Diabetes 116:554-7. 2008
  10. ncbi Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data
    B Gallwitz
    Department of Medicine IV, Eberhard Karls University, Tubingen, Germany
    Int J Clin Pract 60:1654-61. 2006

Collaborators

Detail Information

Publications11

  1. doi 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
    Baptist Gallwitz
    Department of Medicine IV, Universitatsklinikum Tubingen, Tubingen, Germany
    Lancet 380:475-83. 2012
    ..We aimed to compare a dipeptidyl peptidase-4 inhibitor (linagliptin) against a commonly used sulphonylurea (glimepiride)...
  2. doi Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
    Baptist Gallwitz
    Department of Medicine IV, Eberhard Karls University Tubingen, Tubingen, Germany
    Lancet 379:2270-8. 2012
    ..We compared add-on exenatide with glimepiride for durability of glycaemic control in patients with type 2 diabetes inadequately controlled by metformin alone...
  3. doi Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time
    B Gallwitz
    Department of Medicine IV, University Hospital of Tubingen, Tubingen, Germany
    Int J Clin Pract 64:267-76. 2010
    ..To investigate the onset of treatment effects over time observed for liraglutide in combination with oral antidiabetic drugs (OADs)...
  4. doi The risk allele load accelerates the age-dependent decline in beta cell function
    A Haupt
    Medical Clinic, Department of Internal Medicine IV Diabetology, Endocrinology, Nephrology, Angiology, and Clinical Chemistry, Eberhard Karls University, Otfried Muller Strasse 10, 72076, Tubingen, Germany
    Diabetologia 52:457-62. 2009
    ..In the present study we examined the effect of these genes' risk alleles on the age-dependent decline in insulin secretion...
  5. doi A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion
    S A Schafer
    Department of Internal Medicine, Division of Endocrinology, University Hospital of Tubingen, Tubingen, Germany
    Diabetologia 52:1075-82. 2009
    ..We aimed to investigate the effect of a common WFS1 single-nucleotide polymorphism on several aspects of insulin secretion...
  6. doi Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas
    B Gallwitz
    Department of Internal Medicine IV, University of Tubingen, Tubingen, Germany
    Diabetes Obes Metab 12:1-11. 2010
    ..The effects of sulphonylureas and DPP-4 inhibitors on beta-cell function and beta-cell mass are highlighted. The present and future indications for both sulphonylureas and DPP-4 inhibitors are discussed...
  7. doi Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors
    K Müssig
    Division of Endocrinology, Department of Internal Medicine, University Hospital of Tubingen, Tubingen, Germany
    Horm Metab Res 42:599-606. 2010
    ..Negativity for SST2, however, does not rule out tracer uptake in some patients, with heterogeneous SST2 expression within the tumor as a potential explanation...
  8. ncbi Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor
    M Haap
    Department of Endocrinology, Metabolism, Nephrology, Clinical Chemistry and Vascular Medicine, Eberhard Karls University of Tubingen, Tubingen, Germany
    J Endocrinol Invest 30:688-92. 2007
    ..Physicians treating patients with imatinib should be aware of the possible occurrence of hypoglycemic episodes in non-diabetic patients...
  9. doi Lymph node gastrinoma in multiple endocrine neoplasia type 1 - a diagnostic challenge
    K Müssig
    Division of Endocrinology, Diabetology, Nephrology, Angiology, and Clinical Chemistry, Department of Internal Medicine, University Hospital of Tubingen, Tubingen, Germany
    Exp Clin Endocrinol Diabetes 116:554-7. 2008
    ..Gastrinomas are the most frequent hormonally-active neuroendocrine tu-mours in patients with multiple endocrine neoplasia type 1 (MEN1)...
  10. ncbi Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data
    B Gallwitz
    Department of Medicine IV, Eberhard Karls University, Tubingen, Germany
    Int J Clin Pract 60:1654-61. 2006
    ..This review gives an overview on exenatide, its pharmacological profile and its role and potential in the therapeutic setting of type 2 diabetes. Furthermore, future developments concerning exenatide application are highlighted...
  11. pmc Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms
    S A Schafer
    Division of Endocrinology, Diabetology, Vascular Medicine, Nephrology and Clinical Chemistry, Department of Internal Medicine, Eberhard Karls University of Tubingen, Otfried Muller Str 10, 72076, Tubingen, Germany
    Diabetologia 50:2443-50. 2007
    ..We studied whether a defect in the enteroinsular axis contributes to impaired insulin secretion in carriers of TCF7L2 polymorphisms...